Quantcast
Home > Quotes > FGEN

FibroGen, Inc Common Stock (FGEN) Quote & Summary Data

FGEN 
$39.55
*  
0.18
0.46%
Get FGEN Alerts
*Delayed - data as of Dec. 14, 2018  -  Find a broker to begin trading FGEN now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
75
Today's High / Low
$ 40.5673 / $ 38.56
Share Volume
548,209
50 Day Avg. Daily Volume
627,206
Previous Close
$ 39.37
52 Week High / Low
$ 68.55 / $ 37.27
Market Cap
3,360,882,115
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -1.55
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
1.01

Intraday Chart

Shares Traded

Share Volume:
548,209
50 Day Avg. Daily Volume:
627,206

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -1.55

Trading Range

The current last sale of $39.55 is 6.12% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 40.5673 $ 68.55
 Low: $ 38.56 $ 37.27

ETFs with FGEN as a Top 10 Holding*

Weighting ETF Name (Symbol) 100-Day Price Change (%)
256% ALPS Medical Breakthroughs ETF (SBIO) -7.28 (-18.66%)
*Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change.
**Green highlights the top performing ETF by % change in the past 100 days.

Company Description (as filed with the SEC)

We are a science-based biopharmaceutical company discovering and developing first-in-class therapeutics. Roxadustat (FG-4592), our most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase ("HIF-PH") activity in Phase 3 clinical development for the treatment of anemia in chronic kidney disease ("CKD"). Pamrevlumab (FG-3019), a fully-human monoclonal antibody that inhibits the activity of connective tissue growth factor ("CTGF"), is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis ("IPF"), pancreatic cancer, and Duchenne muscular dystrophy ("DMD"). We have taken a global approach to the development and future commercialization of our product candidates, which includes development and commercialization in the People's Republic of China ("China").  ... More ...  


Risk Grade

Where does FGEN fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 38.58
Open Date:
Dec. 14, 2018
Close Price:
$ 39.55
Close Date:
Dec. 14, 2018

Consensus Recommendation

Analyst Info